IS6811A - Lyfjafræðilegar samsetningar NMDA viðtakagerandefna - Google Patents
Lyfjafræðilegar samsetningar NMDA viðtakagerandefnaInfo
- Publication number
- IS6811A IS6811A IS6811A IS6811A IS6811A IS 6811 A IS6811 A IS 6811A IS 6811 A IS6811 A IS 6811A IS 6811 A IS6811 A IS 6811A IS 6811 A IS6811 A IS 6811A
- Authority
- IS
- Iceland
- Prior art keywords
- pharmaceutical compositions
- receptor agonists
- nmda receptor
- nmda
- agonists
- Prior art date
Links
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25537200P | 2000-12-13 | 2000-12-13 | |
| PCT/IB2001/002359 WO2002047685A2 (en) | 2000-12-13 | 2001-12-05 | Nmda receptor agonist pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS6811A true IS6811A (is) | 2003-05-08 |
Family
ID=22968017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS6811A IS6811A (is) | 2000-12-13 | 2003-05-08 | Lyfjafræðilegar samsetningar NMDA viðtakagerandefna |
Country Status (41)
| Country | Link |
|---|---|
| US (2) | US6635270B2 (is) |
| EP (1) | EP1347760B1 (is) |
| JP (1) | JP2004515529A (is) |
| KR (1) | KR100533407B1 (is) |
| CN (1) | CN1273135C (is) |
| AP (1) | AP1235A (is) |
| AR (1) | AR035607A1 (is) |
| AT (1) | ATE296629T1 (is) |
| AU (2) | AU1845402A (is) |
| BG (1) | BG107788A (is) |
| BR (1) | BR0116085A (is) |
| CA (1) | CA2431172A1 (is) |
| CZ (1) | CZ20031543A3 (is) |
| DE (1) | DE60111265T2 (is) |
| DO (1) | DOP2001000300A (is) |
| DZ (1) | DZ3484A1 (is) |
| EA (1) | EA006489B1 (is) |
| EC (1) | ECSP034655A (is) |
| EE (1) | EE200300284A (is) |
| ES (1) | ES2239648T3 (is) |
| GE (1) | GEP20053568B (is) |
| HR (1) | HRP20030473A2 (is) |
| HU (1) | HUP0400645A2 (is) |
| IL (1) | IL155810A0 (is) |
| IS (1) | IS6811A (is) |
| MA (1) | MA26970A1 (is) |
| MX (1) | MXPA03005257A (is) |
| NO (1) | NO20032678L (is) |
| NZ (1) | NZ525742A (is) |
| OA (1) | OA12414A (is) |
| PA (1) | PA8534901A1 (is) |
| PE (1) | PE20020710A1 (is) |
| PL (1) | PL362080A1 (is) |
| PT (1) | PT1347760E (is) |
| SK (1) | SK6982003A3 (is) |
| TN (1) | TNSN01173A1 (is) |
| UA (1) | UA73619C2 (is) |
| UY (1) | UY27068A1 (is) |
| WO (1) | WO2002047685A2 (is) |
| YU (1) | YU41103A (is) |
| ZA (1) | ZA200303892B (is) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20150037T4 (hr) | 2003-04-08 | 2022-09-02 | Progenics Pharmaceuticals, Inc. | Farmaceutske formulacije koje sadrže metilnaltrekson |
| TW200800959A (en) * | 2005-06-10 | 2008-01-01 | Wyeth Corp | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor |
| TW200808741A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts |
| TW200811144A (en) * | 2006-06-09 | 2008-03-01 | Wyeth Corp | Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline |
| TW200808740A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof |
| TWI489984B (zh) | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
| CL2007003410A1 (es) * | 2006-11-28 | 2008-04-11 | Wyeth Corp | Compuestos derivados de 5-fluoro-8-{4-[4-(6-metoxiquinolin-8-il)piperazin-1-il]piperidin-1-il}quinolina; procedimiento de preparacion; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de trast |
| TW200901974A (en) * | 2007-01-16 | 2009-01-16 | Wyeth Corp | Compounds, compositions, and methods of making and using them |
| CN101317844B (zh) * | 2007-06-08 | 2010-11-17 | 章劲夫 | 化合物(+)-5-甲基-10，11-二氢-5H-二苯并〔a，d〕环庚烯-5，10-亚胺在制备避孕药物中的应用 |
| JP5702288B2 (ja) | 2008-09-18 | 2015-04-15 | ノースウエスタン ユニバーシティ | Ｎｍｄａレセプターモジュレータ及びその用途 |
| US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| JP5928828B2 (ja) | 2010-02-11 | 2016-06-01 | ノースウエスタン ユニバーシティ | Ｎｍｄａ受容体モジュレータを安定化させる二次構造及びその使用 |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| CN102586243A (zh) * | 2012-03-08 | 2012-07-18 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 一种预防电磁辐射致脑损伤的标志物 |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| HUE043843T2 (hu) | 2013-01-29 | 2019-09-30 | Aptinyx Inc | Spiro-laktám NMDA receptor modulátorok és azok alkalmazása |
| BR112015018095A2 (pt) | 2013-01-29 | 2017-07-18 | Naurex Inc | moduladores de receptor nmda de espiro-lactama e usos dos mesmos |
| WO2014120784A1 (en) | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| WO2014120800A1 (en) | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| US9758525B2 (en) | 2013-01-29 | 2017-09-12 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| MX2016008369A (es) | 2013-12-23 | 2016-12-15 | Samyang Biopharmaceuticals | Composicion farmaceutica que incluye palonosetron. |
| WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| SG11201810280YA (en) | 2016-05-19 | 2018-12-28 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and uses thereof |
| JP2019527233A (ja) | 2016-08-01 | 2019-09-26 | アプティニックス インコーポレイテッド | スピロ−ラクタムｎｍｄａ受容体修飾因子及びその使用 |
| KR102538803B1 (ko) | 2016-08-01 | 2023-06-01 | 앱티닉스 인크. | 스피로-락탐 nmda 조정제 및 그의 사용 방법 |
| IL286107B2 (en) | 2016-08-01 | 2024-09-01 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and usesthereof |
| JP7036792B2 (ja) | 2016-08-01 | 2022-03-15 | アプティニックス インコーポレイテッド | スピロ－ラクタムｎｍｄａ受容体修飾因子およびその使用 |
| AU2017306158B2 (en) | 2016-08-01 | 2021-10-14 | Aptinyx Inc. | Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof |
| SG11202007256PA (en) | 2018-01-31 | 2020-08-28 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and uses thereof |
| US12012413B2 (en) | 2019-11-11 | 2024-06-18 | Tenacia Biotechnology (Hong Kong) Co., Limited | Methods of treating painful diabetic peripheral neuropathy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5272160A (en) | 1989-05-17 | 1993-12-21 | Pfizer Inc | 2-piperidino-1-alkanol derivatives as antiischemic agents |
| US5710168A (en) * | 1991-10-23 | 1998-01-20 | Pfizer Inc. | 2-piperidino-1-alkanol derivatives as neuroprotective agents |
| EP0843661B1 (en) * | 1995-08-11 | 2002-03-27 | Pfizer Inc. | (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethanesulfonate trihydrate |
| TW450807B (en) * | 1995-09-15 | 2001-08-21 | Pfizer | Pharmaceutical compositions for treating tinnitus comprising neuroprotective agents |
-
2001
- 2001-05-12 UA UA2003065485A patent/UA73619C2/uk unknown
- 2001-12-05 NZ NZ525742A patent/NZ525742A/en unknown
- 2001-12-05 MX MXPA03005257A patent/MXPA03005257A/es active IP Right Grant
- 2001-12-05 YU YU41103A patent/YU41103A/sh unknown
- 2001-12-05 DE DE60111265T patent/DE60111265T2/de not_active Expired - Fee Related
- 2001-12-05 AT AT01270205T patent/ATE296629T1/de not_active IP Right Cessation
- 2001-12-05 AU AU1845402A patent/AU1845402A/xx active Pending
- 2001-12-05 CN CNB018203922A patent/CN1273135C/zh not_active Expired - Fee Related
- 2001-12-05 CZ CZ20031543A patent/CZ20031543A3/cs unknown
- 2001-12-05 BR BR0116085-0A patent/BR0116085A/pt not_active IP Right Cessation
- 2001-12-05 IL IL15581001A patent/IL155810A0/xx unknown
- 2001-12-05 EE EEP200300284A patent/EE200300284A/xx unknown
- 2001-12-05 SK SK698-2003A patent/SK6982003A3/sk unknown
- 2001-12-05 ES ES01270205T patent/ES2239648T3/es not_active Expired - Lifetime
- 2001-12-05 KR KR10-2003-7007874A patent/KR100533407B1/ko not_active Expired - Fee Related
- 2001-12-05 EP EP01270205A patent/EP1347760B1/en not_active Expired - Lifetime
- 2001-12-05 HR HR20030473A patent/HRP20030473A2/hr not_active Application Discontinuation
- 2001-12-05 DZ DZ013484A patent/DZ3484A1/fr active
- 2001-12-05 OA OA1200300145A patent/OA12414A/en unknown
- 2001-12-05 US US10/010,827 patent/US6635270B2/en not_active Expired - Fee Related
- 2001-12-05 PT PT01270205T patent/PT1347760E/pt unknown
- 2001-12-05 HU HU0400645A patent/HUP0400645A2/hu unknown
- 2001-12-05 GE GE5171A patent/GEP20053568B/en unknown
- 2001-12-05 PL PL01362080A patent/PL362080A1/xx not_active Application Discontinuation
- 2001-12-05 JP JP2002549256A patent/JP2004515529A/ja active Pending
- 2001-12-05 CA CA002431172A patent/CA2431172A1/en not_active Abandoned
- 2001-12-05 EA EA200300514A patent/EA006489B1/ru not_active IP Right Cessation
- 2001-12-05 WO PCT/IB2001/002359 patent/WO2002047685A2/en not_active Application Discontinuation
- 2001-12-05 AU AU2002218454A patent/AU2002218454B2/en not_active Ceased
- 2001-12-10 DO DO2001000300A patent/DOP2001000300A/es unknown
- 2001-12-11 AR ARP010105748A patent/AR035607A1/es unknown
- 2001-12-11 PE PE2001001235A patent/PE20020710A1/es not_active Application Discontinuation
- 2001-12-12 TN TNTNSN01173A patent/TNSN01173A1/fr unknown
- 2001-12-12 UY UY27068A patent/UY27068A1/es not_active Application Discontinuation
- 2001-12-13 AP APAP/P/2001/002376A patent/AP1235A/en active
- 2001-12-13 PA PA20018534901A patent/PA8534901A1/es unknown
-
2003
- 2003-05-08 IS IS6811A patent/IS6811A/is unknown
- 2003-05-09 BG BG107788A patent/BG107788A/bg unknown
- 2003-05-20 ZA ZA200303892A patent/ZA200303892B/en unknown
- 2003-06-03 MA MA27191A patent/MA26970A1/fr unknown
- 2003-06-12 NO NO20032678A patent/NO20032678L/no not_active Application Discontinuation
- 2003-06-13 EC EC2003004655A patent/ECSP034655A/es unknown
- 2003-08-19 US US10/643,441 patent/US20040039022A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS6811A (is) | Lyfjafræðilegar samsetningar NMDA viðtakagerandefna | |
| FR2795324B1 (fr) | Compositions pharmaceutiques stabilisees | |
| AR028204A1 (es) | Composiciones farmaceuticas electrohiladas | |
| ITMI20010748A0 (it) | Composizioni farmaceutiche | |
| DK1446379T3 (da) | Arylanilin-beta2-adrenergiske receptoragonister | |
| DK1524266T3 (da) | Farmaceutisk sammensætning | |
| EE05378B1 (et) | LahustuvaÁCTLA4ÁsulandmolekuliÁkasutamineÁravimkoostiseÁvalmistamiseks | |
| NO20025450L (no) | Ny farmasöytisk sammensetning | |
| FI20011478A0 (fi) | Farmaseuttinen koostumus | |
| AT7729U3 (de) | Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat | |
| EE05020B1 (et) | Glburiidi ravimkoostis | |
| EG24194A (en) | 5ht-a-partial agonist pharmaceutical compositions | |
| EE200300589A (et) | Ravimkoostised | |
| IS2481B (is) | Lyfjablanda sem inniheldur 5HT1 viðtakagerandefni | |
| NO20026123L (no) | Farmasöytiske sammensetninger | |
| NO20042272L (no) | Farmasoytiske blandinger og fremgangsmater for administrering av EP2-reseptor selektive agonister | |
| NO20031095L (no) | Farmasoytiske sammensetninger | |
| EE200300465A (et) | Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid | |
| DK1347760T3 (da) | Farmaceutiske kompositioner med NMDA receptor agonister | |
| EE200200689A (et) | Ravimkoostised | |
| DK1307264T3 (da) | Hidtil ukendt farmaceutisk præparat | |
| SE0000934D0 (sv) | Method of preparing pharmaceutical compositions |